Application value of Camrelizumab combined with GP chemotherapy in non-small cell lung cancer
CHEN Lei1 CAO Qisheng1 WANG Yuqin1 HUANG Qi2
1.Department of Interventional Oncology, Maanshan People’s Hospital, Anhui Province, Maanshan 243000, China;
2.Department of Oncology, the Second Hospital of Anhui Medical University, Anhui Province, Hefei 230000, China
Abstract：Objective To investigate the effect of Camrelizumab combined with GP chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Methods A total of 62 patients with NSCLC admitted to Maanshan People’s Hospital of Anhui Province from June 2019 to February 2021 were selected as the research subjects, and they were divided into single group and combined group according to random drawing, with 31 cases in each group. The single group was treated with GP chemotherapy, and the combined group was treated with Camrelizumab combined with GP chemotherapy. Clinical effects of two groups were compared. The indexes of pulmonary function (forced vital capacity [FVC], forced expiratory volume in the first second [FEV1], maximum ventilation volume [MVV], and immune function (CD4+, CD3+, CD8+) were compared between two groups before treatment and six cycles of treatment. Results Clinical effect of combined group was better than that of single group, and the difference was statistically significant (P ＜ 0.05). Six cycles of treatment, FVC, FEV1, and MVV in two groups were higher than those before treatment, and those in combined group were higher than those in single group, the differences were statistically significant (P ＜ 0.05). Six cycles of treatment, the levels of CD4+ and CD3+ in two groups were higher than those before treatment, and the levels of CD8+ in two groups were lower than those before treatment (P ＜ 0.05), and the levels of CD4+ and CD3+ in combined group were higher than those in single group, and the level of CD8+ in combined group was lower than that in single group, the differences were statistically significant (P < 0.05). Conclusion Camrelizumab combined with GP chemotherapy has a significant effect in the treatment of NSCLC, and can improve the lung function and immune function of patients.
陈磊1 曹齐生1 王玉琴1 黄琦2. 卡瑞丽珠单抗联合GP化疗在非小细胞肺癌中的应用价值[J]. 中国医药导报, 2022, 19(20): 92-95.
CHEN Lei1 CAO Qisheng1 WANG Yuqin1 HUANG Qi2. Application value of Camrelizumab combined with GP chemotherapy in non-small cell lung cancer. 中国医药导报, 2022, 19(20): 92-95.
京公网安备 11010502046598号